The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 5,196 followers.

The authors of "The BRD4 inhibitor JQ1 augments the antitumor effi…" (https://t.co/3nbbkKx1cI) included RRIDs in their paper! Thank you for making your #methodsmatter. #reproducibility

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models o... https://t.co/ObyqXeVtnY

RT @JournalofExper1: Online!💻 The BRD4 inhibitor JQ1 augments the antitumor efficacy of #abemaciclib in #preclinicalmodels of #gastriccarc…

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma https://t.co/PyhSMNlfhr

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.